HCV treatment of injecting drug users in the czech republic - Survey among viral hepatitis treatment centres;Léčba VHC u injekčních uživatelů drog v ČR - Průzkum mezi centry pro léčbu virových hepatitid

Adiktologie

Volumn 12, Issue 1, 2012, Pages 10-22

  Mravčík, Viktor ^a,b  

^a National Monitoring Centre for Drugs and Drug Addiction   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adherence; Efficacy; Injecting drug use; Interferon; Methamphetamine; Ribavirin; Treatment; Viral hepatitis C

Indexed keywords

EID: 84864243591     PISSN: 12133841     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Alvarez-Uria, G., Day, J N., Nasir, A. J., Russell, S. K. & Vilar, F. J. (2009). Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver International. 29(7), 1051-1055.
2. Ascione, A., Tartaglione, T. & Di Costanzo, G. G. (2007). Natural history of chronic hepatitis C virus infection. Digestive and Liver Disease Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 39(Suppl. 1), pp. 4-7.
3. Backmund. M., Meyer, K., Von Zielonka, M. & Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection druQ ussrs. HBpdtology, 34(1), 188-193. (Pubitemid 32591499)
4. Boykinova, O. B., Stoilova, V. D., Tsvetkova. T. Z.. Baltadjiev, I. G (2009). Epidemiological, immunological and clinical characteristics of acute hepatitis C. Folia Med. (Plovdiv) 51(1):61-69.
5. Dalgard, O., Bjoro, K., Helium, K., Myrvang, B , Skaug, K. , Gutigard, B , Bell, H. & Construct Group. (2002). Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur. Addict. Res., 8(1), 45-49. (Pubitemid 34701984)
6. Davis, G. L., Alter, M. J., El-Serag, H.. Poynard, T. & Jennings, L. W. (2010). Aging of hepatitis C virus (HCVHnfected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology, 138(2),513-521.
7. Dore, G. J., Hellard, M., Matthews, G. V., Grebely, J., Haber, P. S.. Petou-menos, K., Yeung, B. Marks, P., van Beek, l., McCaughan, G., White, P., French, R., Rawlinson, W., Lloyd A. R., Kaldor. J. M. & Australian Trial In Acute Hepatitis C Study Group. (2010). Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology, 138(1), 123-135.
8. Dumchev, K. V., Soldyshev, R., Qian, H. Z., Zezyulin, O. O., Chandler, S. D., Slobodyanyuk, P.. Moroz, L. & Schumacher, J. E. (2009). HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey. Harm Reduction Journal, 6, 23
9. Edlin, B R. (2002). Prevention and treatment of hepatitis C in injection drug users. Hepatology. 36(5 Suppl. 1), pp. 210-219.
10. European Monitoring Centre for Drugs and Drug Addiction. (2010). Annual Report2010. The State of the Drugs Problem in Europe. Luxembourg: Publications Office of the European Union.
11. Galský, J.. Husa, P., Kümpel. P.. Plíšek, S., Šperl, J., Urbánek, P., Dvořáček, J., Popov, P. & Zábranský, T. (2008). Standard pro léčbu virových hepatitid u uživatelů drog. Věstník Ministerstva zdravotnictví ČR (Částka 7/2008, č.j. 28629/2008).
12. Gane, E. (2011). Future hepatitis C virus treatment: interferon-sparing combinations. Liver International, 31(Supplement 1), 62-67.
13. Gazdik, F., Gazdikova, K., Laktis, K., Okruhlica, L., Fejdiova, K., Danis, D., Piják, M. R., Wsolova, L., Kajaba, I. & Kratky, A. (2009). High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin. Bratisl. lek. listy, 110(2), 77-84.
14. Grebely. J., Genoway, K., Khara, M.,Duncan, F., Viljoen, M., Elliott, D., Raf-fa, J. D , DeVlaming, S. & Conway, B. (2007). Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int. J. Drug. Policy, 18(5), 437-443. (Pubitemid 47381422)
15. Grebely, J , Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T., Showier, G., Kalousek, K., Duncan, F., Tyndall, M. W , Fraser, C., Conway, B. & Fischer, B. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93(1-2), 141-147. (Pubitemid 350245718)
16. Grebely, J., Knight, E., Ngai, T., Genoway, K. A., Raffa, J. D., Storms, M., Gallagher, L., Krajden, M., Dore, G. J., Duncan, F., Conway, B.( 2010a). Reinfection with hepatitis C virus following sustained virological response in injection drug users. J. Gastroenterol. Hepatol., 2010a Jul;25(7): 1281-1284.
17. Grebely, J , Petoumenos, K., Matthews, G V.. Haber, P., Marks. P., Lloyd. A. R., Kaldor, J. M., Dore, G. J., Hellard, M. & ATAHC Study Group. (2010b). Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug and Alcohol Dependence, 107(2-3), 244-249.
18. Grebely, J . Pham, S. T., Matthews. G V., Petoumenos, K., Bull, R. A., Yeung, B., Rawlinson, W , Kaldor, J., Lloyd, A., Hellard, M., Dore, G. J . White, P. A. & ATAHC Study Group (2011). Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2011, Oct. 26. [Epub ahead of print).
19. Hagan, H., Strauss, S. M., Astone, J. M. & Des Jarlais, D. C. (2005). Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin. Infect. Dis., 40(Supplement 5), pp. 297-303.
20. Hallinan, R., Byrne, A., Agho, K.& Dore, G J (2007). Referral for chronic hepatitis C treatment from a drug dependency treatment setting . Drug and Alcohol Dependence, 88(1), 49-53. (Pubitemid 46400306)
21. Holtzman, D., Barry, V., Ouellet, L. J.. Des Jarlais, D. C.. Vlahov, D., Golub, E. T., Hudson, S. M. & Garfein, R. S. (2009). The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004 . Preventive Medicine. 49(1), 68-73.
22. Hopwood, M & Treloar, C. (2007). The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. The International Journal of Drug Policy, 18(5), 374-380. (Pubitemid 47374499)
23. John-Baptiste, A., Krahn, M., Heathcote, J., Laporte, A. & Tomlinson, G. (2010). The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression. Journal of Hepatology, 53(2 ), 245-251.
24. Kamal. S. M. (2008). Acute hepatitis C: a systematic review. American Journal of Gastroenterology. 103(5), 1283-1297. (Pubitemid 351677997)
25. Krekulová. L. Řehák, V. & Riley, L. W. (2002). Zastoupení genotypů HCV v Praze. Čes. slov. gastroent., 56(2), 61-66.
26. Krekulová, L., ftehák, V., Strumecký, O. & Němeček, V. (2009). Situace a trendy v zastoupení genotypů viru hepatitidy C v populaci injekčních uživatelů drog. Epidemiol. Mikrobiol. Imunol., 58(2), 84-89.
27. Lindenburg, C. E., Lambers, F. A., Urbanus, A. T., Schinkel, J., Jansen, P. L., Krol, A., Casteelen, G., van Santen, G., van den Berg. Ch., Coutinho, R. A. Prins, M. & Weegink, C. J. (2011). Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. European Journal of Gastroenterology b Hepatology, 23(1), 23-31.
28. Litwin, A. H., Soloway, I. & Gourevitch, M. N. (2005). Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment, challenges and opportunities . Clinical Infectious Diseases. 40(Supplement 5), pp. 339-345.
29. Loomba, R., Rivera, M. M., McBurney, R., Park, Y., Haynes-Williams, V., Rehermann, B., Alter, H. J., Herrine, S. K., Liang, T. J. Hoofnagle. J. H. & Heller, T. (2011). The natural history of acute hepatitis C: Clinical presentation, laboratory findings and treatment outcomes. Alimentary Pharmacology b Therapeutics, 33(5), 559-565.
30. Martin, N K., Vickerman, P., & Hickman, M. (2011). Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theoretical Biology. 274(1), 58-66
31. Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D. Vlahov, D., Strathdee, S. A. & Thomas, D. L. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33(3), 126-133
32. Melin, P., Chousterman, M., Fontanges, T. Ouzan, D , Rotily, M., Lang, J P., Marcellin, P., Cacoub, P. & Cheobs Study Group. (2010). Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: Resultsof a prospective cohort study European Journal of Gastroenterology b Hepatology, 22(9). 1050-1057.
33. Miller, E. R., Hellard, M. E., Bowden, S., Bharadwaj, M. & Aitken, C. K. (2009). Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. Journal of Infection, 58(5), 375-382.
34. Moussalli, J., Delaquaize, H., Boubilley, D. Lhomme. J. P., Merleau Ponty, J., Sabot, D. Kerever, A., Valleur. M. & Poynard, T. (2010). Factors to improve the management of hepatitis C in drug users: An observational study in an addiction centre. Gastroenterology Research and Practice, 2010 (ID 261472), 4 pages.
35. Mravčík. V , Petrošová, B., Zábranský, T., Coufalová, M. & Řehák, V. (2009). Výskyt VHC u injekčnfch uživatelů drog. Výsledky studie prováděné mezi klienty nfzkoprahových zařízení v letech 2002-2005. Praha: Úřad vlády ČR. Notes: Publikováno v ediční řade e-knihovna NMS.
36. Mravčík, V., Pešek. R. Horáková, M., Nečas, V., Chomynová, P., Štastná, L., Grolmusová, L., Kiššová, L., Fidesová, H., Nechanská, B., Vopravil, J., Pres-lová, I., Dolež alová, P. & Koňák, T. (2011a). Annual Report. The Czech Republic 2010 Drug Situation. Prague: Office of the Government of the Czech Republic.
37. Mravčík, V., Pešek, R. Horáková, M., Nečas, V., Chomynová. P. Štastná, L., Grolmusová, L., Kiššová, L., Fidesová, H., Nechanská, B., Vopravil. J., Pres-lová, l., Dolež alová, P. & Koňák, T. (2011 b). Výroč ní zpráva o stavu ve věcech drog v České republice v roce 2010. Praha: Úřad vlády ČR.
38. Mravčík, V. & Šebáková, H. (2002). Výskyt virových hepatitid typu B a C u in-jekčních uživatelů drog v okrese Karviná. Adiktologie, 2(2), 19-27.
39. Nechanská, B. (2011). Péče o pacienty užívajícípsychoakttvnílátky v ambulantních zařízeních ČR v roce 2010. Aktuální informace č 23/2011. Praha: ÚZIS ČR.
40. Nguyen, O. K., Dore, G. J. Kaldor, J. M. & Hellard, M. E. (2007). Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: Insights from the ATAHC study. The International Journal of Drug Policy, 18(5), 447-451. (Pubitemid 47376914)
41. Painsil, E., Verevochkin, S. V. Dukhovlinova, E., Niccolai, L., Barbour. R., White, E. Toussova, O. V., Alexander, L., Kozlov. A P. & Heimer, R. (2009). Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction, 104(11), 1881-1890.
42. Pérez-Álvarez, R., García-Samaniego, J., Solá, R., Pérez-López. R., Bárce-na. R., Planas, R. Caňete, N., Manzano, M. L., Gutiérrez, M. L., Morano, L., Rodrigo, L. (2012). Acute hepatitis C in Spain: a retrospective study of 131 cases. Rev. Esp. Enferm. Dig. Feb; 104(1):21-28.
43. Piatt, L., Sutton, A. J., Vickerman, P., Koshkina, E., Maximova, S., Latishev-skaya, N , Hickman, M. Bonell, C., Parry, J. & Rhodes, T. (2009). Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. European Journal of Public Health, 19(4), 428-433.
44. Robaeys, G., Van Vlierberghe. H., Mathei. C., Van Ranst, M., Bruckers, L., Buntinx, F., BASL Steering Committee & Benelux Study Group. (2006). Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur. J. Gastroenterol. Hepatol., 18(2), 159-166. (Pubitemid 43361601)
45. Roy, K., Hay, G., Andragetti, R., Taylor, A, Goldberg, D. & Wiessing, L. (2002). Monitoring hepatitis C virus infection among injecting drug users in the European Union: A review of the literature. Epidemiol. Infect., 129(3), 577-585. (Pubitemid 36157682)
46. Roy, K. M., Hutchinson, S. J., Wadd, S., Taylor, A., Cameron, S. O., Burns, S., Molyneaux, P., Mclntyre, P. G. & Goldberg, D. J. (2007). Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol. Infect., 135(3). 433-442. (Pubitemid 46443429)
47. Schaefer, M., Hinzpeter, A., Mohmand, A., Janssen, G., Pich, M., Schwai-ger, M., Sarkar. R., Friebe, A., Heinz, A., Kluschke, M., Ziemer, M., Gutsche, J., Weich, V., Halangk, J. & Berg, T. (2007). Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology, 46(4), 991-998. (Pubitemid 350144763)
48. Slezáková, S. & Okruhlica, L. (2011). Motivácia na liečbu hepatitídy C u uží-vaterov psychoaktívnych látok .Adiktologie, 11(3), 142-146.
49. Stein, M. D , Herman, D. S. & Anderson, B. J. (2009). A trial to reduce hepatitis C seroincidence in drug users. Journal of Addictive Diseases, 28(4), 389-398.
50. Strauss, S. M. Astone, J., Vassilev, Z. P., Des Jarlais, D. C. & Hagan, H. (2003). Gaps in the drug-free and methadone treatment program response to hepatitis C.J. Subst. Abuse Treat. 24(4), 291-297. (Pubitemid 36809281)
51. Strauss, S. M . Falkin, G. P., Vassilev, Z., Des Jarlais, D. C. & Astone, J. (2002). A nationwide survey of hepatitis C services provided by drug treatment programs. J. Subst. Abuse Treat. 22(2), 55-62. (Pubitemid 34257980)
52. Studničková, B. & Petrášová. B (2011). Výroční zpráva ČR-2010. Incidence, prevalence, zdravotní dopady a trendy léčených uživatelů drog. Praha: Hygienická stanice hl. m. Prahy, referát drogové epidemiologie.
53. Státní zdravotní ústav Praha. (2011). Virové hepatitidy 1996-2010 (EPIDAT) - analýza pro účely VZ2010. Notes: Nepublikováno
54. Sylvestre, D L. & Clements, B. J. (2007). Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur. J. Gastroenterol. Hepatol., 19(9), 741-747. (Pubitemid 47266701)
55. Teasdale, K. E., Keren, K. M., Kiel, A. & Becker, K. (2008). Improving services for prevention and treatment of substance misuse for Aboriginal communities in a Sydney Area Health Service. Drug and Alcohol Review, 27(2), 152-159.
56. Treloar, C., Newland, J., Ranee, J. & Hopwood, M. (2010). Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J. Viral. Hepat., 17(12), 839-844.
57. Tungol, A, Rademacher, K. & Schafer, J. A. (2011). Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J. Manag. Care Pharm., Nov; 17(9), 685-94.
58. Van Den Berg, C. H., Grady. B P., Schinkel, J., van de Laar, T., Molenkamp, R., van Houdt, R., Coutinho, R. A., van Baarle, D. Prins, M. (2011). Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort PLoS One, 6(11).
59. Van Thiel, D. H., Anantharaju, A. & Creech, S. (2003). Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am. J. Gastroenterol., 98(10), 2281-2288. (Pubitemid 37305371)
60. Vickerman, P., Martin, N. & Hickman, M. (2010). Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere . Drug and Alcohol Dependence. 113(2-3), 83-85.
61. Wiessing, L. Guarita, B., Giraudon, I., Brummer-Korvenkontio, H., Salmi-nen, M. & Cowan, S. A. (2008). European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability Eurosurveillance, 13(21).
62. Xia, X., Luo, J., Bai. J & Yu, R. (2008). Epidemiology of hepatitis C virus infection among injection drug users in China: Systematic review and meta-analysis. Public Health., 122(10), 990-1003.
63. Zeiler, I. Langlands, T., Murray, J. M. & Ritter, A. (2010). Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend., 110(3), 228-233.
64. Zábranský, T., Mravčík, V. Korčišová, B. & Řehák, V. (2006). Hepatitis C virus infection among injecting drug users in the Czech Republic - prevalence and associated factors. European Addiction Research, 12 (3), 151-160.